Scancell (LON:SCLP) Shares Up 13.3% – Here’s Why

Scancell Holdings plc (LON:SCLP) shares were up 13.3% during mid-day trading on Monday . The company traded as high as GBX 10.24 ($0.14) and last traded at GBX 9.60 ($0.13). Approximately 5,103,223 shares changed hands during mid-day trading, an increase of 520% from the average daily volume of 823,542 shares. The stock had previously closed at GBX 8.48 ($0.11).

Scancell Price Performance

The stock has a market capitalization of £105.90 million, a P/E ratio of -15.68 and a beta of 0.35. The firm has a 50-day moving average price of GBX 8.51 and a 200 day moving average price of GBX 10.85. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42.

Scancell (LON:SCLP) last released its earnings results on Thursday, January 30th. The company reported GBX (1.35) (($0.02)) earnings per share for the quarter. On average, analysts expect that Scancell Holdings plc will post -2.5361112 EPS for the current year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers.

Scancell has developed a pipeline of ‘off-the-shelf’ vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.